Maria F.
- Country
- Greece
- Department
- 4th Department of Pediatrics
Research Overview
- Evaluation of Filgotinib Efficacy, Safety, and Pharmacokinetics in Pediatric Patients with Moderate to Severe Ulcerative Colitis
- Efficacy and Safety Evaluation of Esomeprazole Magnesium in Maintaining Healing of Erosive Esophagitis in Pediatric Patients Aged 1 to 11 Years
- Evaluation of Safety and Tolerability of Single-Dose Intravenous Oritavancin Versus Standard Care in Pediatric Acute Bacterial Skin and Skin Structure Infections
Data & Insights
Has run more than one trial at 11 of 72 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in pediatric ulcerative colitis treatment, focusing on innovative therapeutic approaches for children and adolescents with inflammatory bowel conditions.
- Pediatric UC Management
- Remission Induction Therapies
- Long-term Disease Control
Their work encompasses evaluation of novel therapeutic agents for young patients with inflammatory bowel conditions.
Immunology Studies
The investigator conducts extensive research in Primary Immunodeficiency Diseases (PIDD), evaluating innovative treatment approaches and long-term therapeutic solutions.
- PIDD Treatment Evaluation
- Long-term Safety Assessment
- Immunotherapy Development
Their research focuses on advancing treatment options for patients with primary immune system disorders.
Clinical Pharmacology
The investigator specializes in pharmacokinetic research, particularly in the context of immunological treatments and subcutaneous administration methods.
- Treatment Comparability Studies
- Subcutaneous Administration Research
- Drug Tolerability Assessment
Their work includes evaluation of drug delivery systems and therapeutic effectiveness in immunological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.